Clinical trials: Digestive System Neuroendocrine Tumor G1
Gastrointestinal Carcinoid Tumor, Lung Cancer
Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of the cancer cells.
- Trial name
- NCT00002470
- Testing
- recombinant interferon alfa, fluorouracil
- Where
- United States
- Sponsor
- Mid-Atlantic Oncology Program
Gastroenteropancreatic Neuroendocrine Tumor
Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs
This is a multicentre long-term non-interventional study of adult subjects diagnosed with unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive GEP-NETs who have been prescribed…
- Trial name
- REAL-LU (NCT04727723)
- Testing
- Lutathera®
- Where
- 18 sites in Italy
- Volunteers
- 164 people
- Sponsor
- Novartis Pharmaceuticals
Gastrinoma, Glucagonoma
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
This phase II trial is studying how well sorafenib tosylate works in treating patients with progressive metastatic neuroendocrine tumors.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT00131911
- Testing
- sorafenib tosylate
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- National Cancer Institute (NCI)
Adrenocortical Carcinoma, Gastrointestinal Carcinoid Tumor
Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features
RATIONALE: Seneca Valley virus-001 may be able to kill certain kinds of tumor cells without damaging normal cells. Adding low dose cyclophosphamide (in part B of study) may help to kill even more tumor cells.
- Conditions
- Adrenocortical Carcinoma, Gastrointestinal Carcinoid Tumor, Kidney Cancer, Neuroblastoma
- Trial name
- NCT01048892
- Testing
- Seneca Valley virus-001, cyclophosphamide, laboratory biomarker analysis
- Where
- 18 sites in United States
- Volunteers
- 22 people
- Sponsor
- Children's Oncology Group
Head and Neck Cancer, Islet Cell Tumor
Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Conditions
- Head and Neck Cancer, Islet Cell Tumor, Metastatic Cancer, Pheochromocytoma
- Trial name
- NCT00466856
- Testing
- octreotide acetate, yttrium Y 90 resin microspheres
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
This phase II trial studies how well temsirolimus and bevacizumab work in treating patients with advanced endometrial, ovarian, liver, carcinoid, or islet cell cancer.
- Conditions
- Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Endometrial Serous Adenocarcinoma, Localized Non-Resectable Adult Liver Carcinoma
- Trial name
- NCT01010126
- Testing
- Bevacizumab, Temsirolimus
- Where
- 61 sites in United States, Canada
- Volunteers
- 252 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Gastrointestinal Carcinoid Tumor, Recurrent Gastrointestinal Carcinoid Tumor
Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors
This randomized phase II trial is to see if combining bevacizumab with PEG-interferon alfa-2b works in treating patients who have metastatic or unresectable carcinoid tumors.
- Conditions
- Metastatic Gastrointestinal Carcinoid Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Regional Gastrointestinal Carcinoid Tumor
- Trial name
- NCT00055809
- Testing
- PEG-interferon alfa-2b, bevacizumab, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
HER2-positive Breast Cancer, HER2 Low
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
This is an open-label, single-arm, multi-site phase I/Ib trial with SYD985, an antibody-drug conjugate (ADC) targeting HER2 on the cell membrane, combined with paclitaxel.
- Conditions
- HER2-positive Breast Cancer, HER2 Low, SYD-985, SYD985
- Trial name
- NCT04602117
- Testing
- Vic-trastuzumab duocarmazine (SYD985) + paclitaxel
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- QuantumLeap Healthcare Collaborative
Extrahepatic Bile Duct Cancer, Gastric Cancer
Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells.
- Conditions
- Extrahepatic Bile Duct Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Liver Cancer
- Trial name
- NCT00019474
- Testing
- filgrastim, recombinant interferon alfa, fluorouracil
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Montefiore Medical Center
Anal Cancer, Carcinoma of the Appendix
Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Anal Cancer, Carcinoma of the Appendix, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00654160
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Mayo Clinic
Cancer
Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen
RATIONALE: Antiemetic drugs may help to reduce or prevent vomiting in patients treated with radiation therapy. It is not yet known if ondansetron is more effective with or without dexamethasone in preventing vomiting caused by…
- Trial name
- NCT00016380
- Testing
- dexamethasone, ondansetron, quality-of-life assessment
- Where
- 14 sites in Canada
- Volunteers
- 211 people
- Sponsor
- NCIC Clinical Trials Group
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of PS-341 in treating patients who have metastatic…
- Trial name
- NCT00017199
- Testing
- bortezomib
- Where
- 2 sites in United States
- Sponsor
- Ohio State University Comprehensive Cancer Center
Cancer
Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of aminocamptothecin in treating patients with advanced…
- Trial name
- NCT00003548
- Testing
- aminocamptothecin colloidal dispersion
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- NYU Langone Health
Neoplasms, Neoplasm Metastasis
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
This study is to evaluate the safety and antitumor activity of EMB-01 in advanced/metastatic gastrointestinal cancers, including gastric cancer, hepatocellular cancer, cholangiocarcinoma and colorectal cancer.
- Conditions
- Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT05176665
- Testing
- EMB-01
- Where
- 14 sites in United States, China
- Volunteers
- 152 people
- Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
Pancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2
Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery
This phase II trial studies how well sapanisertib works in treating patients with pancreatic neuroendocrine tumor that has spread to other places in the body (metastatic), does not respond to treatment (refractory), or cannot be…
- Conditions
- Pancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2, Refractory Pancreatic Neuroendocrine Carcinoma
- Trial name
- NCT02893930
- Testing
- Sapanisertib
- Where
- 405 sites in United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction
Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction
RATIONALE: The use of endoscopy to place metal stents in the duodenum is less invasive than surgery for treating cancer-related duodenal obstruction and may have fewer side effects and improve recovery.
- Conditions
- Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction, Extrahepatic Bile Duct Cancer, Gastric Cancer
- Trial name
- NCT00004910
- Testing
- bowel obstruction management, quality-of-life assessment
- Where
- United States
- Sponsor
- Northwestern University
Cancer
Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer
RATIONALE: Learning about the relationship between platinum levels in the blood and neurotoxicity in patients receiving oxaliplatin may help plan treatment and may help patients live more comfortably.
- Trial name
- NCT00274885
- Testing
- oxaliplatin, management of therapy complications
- Where
- 6 sites in France
- Volunteers
- 58 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Gastrinoma, Glucagonoma
Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
This phase II trial studies regorafenib in treating patients with neuroendocrine tumors that have spread from the primary site (place where it started) to other places in the body.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT02259725
- Testing
- regorafenib, laboratory biomarker analysis
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- University of Southern California
Cancer Pain, Visceral Pain
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Patients with digestive tract malignancy often experience severe and unremitting abdominal pain that negatively affects physical, emotional, and social function, as well as health related quality of life (HRQOL).
- Conditions
- Cancer Pain, Visceral Pain, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract
- Trial name
- NCT04907643
- Testing
- PICO G2 4k
- Where
- United States
- Volunteers
- 360 people
- Sponsor
- Cedars-Sinai Medical Center
Anal Cancer, Carcinoma of the Appendix
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
RATIONALE: Palonosetron hydrochloride may prevent nausea and vomiting caused by radiation therapy. It is not yet known whether palonosetron hydrochloride is more effective than a placebo in preventing nausea and vomiting.
- Conditions
- Anal Cancer, Carcinoma of the Appendix, Colorectal Cancer, Extrahepatic Bile Duct Cancer
- Trial name
- NCT00903396
- Testing
- palonosetron hydrochloride
- Where
- 69 sites in United States
- Volunteers
- 7 people
- Sponsor
- Alliance for Clinical Trials in Oncology